Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;16(4):475-483.
doi: 10.2174/1570159X15666171109132650.

Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis

Elzbieta Miller  1   2 , Agnieszka Morel  3 , Justyna Redlicka  1   2 , Igor Miller  1 , Joanna Saluk  3
Affiliations
Review

Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis

Elzbieta Miller et al. Curr Neuropharmacol. 2018.

Abstract

Background: Cognitive impairment is one of the most important clinical features of neurodegenerative disorders including multiple sclerosis (MS). Conducted research shows that up to 65 percent of MS patients have cognitive deficits such as episodic memory, sustained attention, reduced verbal fluency; however, the cognitive MS domain is information processing speed. It is the first syndrome of cognitive dysfunction and the most widely affected in MS. Occasionally these impairments occur even before the appearance of physical symptoms.

Methods: Therefore, this review focused on the current status of our knowledge about possible methods of treatment cognitive impairment in MS patients including novel strategies. Research and online content was performed using Medline and EMBASE databases.

Results: The most recent research suggests that cognitive impairment is correlated with brain lesion volume and brain atrophy. The examination of the cognitive impairment is usually based on particular neuropsychological batteries. However, it can be not enough to make a precise diagnosis. This creates a demand to find markers that might be useful for identifying patients with risk of cognitive impairment at an early stage of the disease. Currently the most promising methods consist of neuroimaging indicators, such as diffusion tensor imaging, the magnetization transfer ratio, and N-acetyl aspartate levels. Diagnosis problems are strictly connected with treatment procedures. There are two main cognitive therapies: pharmacological (disease modifying drugs (DMD), symptomatic treatments) and non-pharmacological interventions that are focused on psychological and physical rehabilitation. Some trials have shown a positive association between physical activity and the cognitive function.

Conclusion: This article is an overview of the current state of knowledge related to cognition impairment treatment in MS. Additionally, novel strategies for cognitive impairments such as cryostimulation and other complementary methods are presented.

Keywords: Multiple sclerosis; cognitive impairment; disease-modifying drugs; neurodegeneration; non-pharmacological therapies; pharmacology..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
The main factors affecting cognitive decline in multiple sclerosis patients.
Fig. (2)
Fig. (2)
Development of cognitive impairment in multiple sclerosis (MS).
See this image and copyright information in PMC

References

    1. Charcot J.M. 1880. Lecons sur les maladies du systeme nerveux faites a la Salpe-triere,1872sc ed.; A. Delahaye: Paris,
    1. Ross A.T., Reitan R.M. Intellectual and affective functions in multiple sclerosis; a quantitative study. AMA Arch. Neurol. Psychiatry. 1955;73(6):663–677. [http://dx.doi.org/10.1001/archneurpsyc. 1955.02330120067007]. [PMID: 14375430]. - PubMed
    1. Langdon D., Holloway R. Introduction to cognition and MS. Cognition and MS; 2013. pp. 4–18.
    1. Morel A., Bijak M., Miller E., Rywaniak J., Miller S., Saluk J. Relationship between the increased haemostatic properties of blood platelets and oxidative stress level in multiple sclerosis patients with the secondary progressive stage. Oxyd. Med. Cell. Longev., 2015. - PMC - PubMed
    1. Brissart H., Morele E., Baumann C., Perf M.L., Leininger M., Taillemite L., Dillier C., Pittion S., Spitz E., Debouverie M. Cognitive impairment among different clinical courses of multiple sclerosis. Neurol. Res. 2013;35(8):867–872. [http://dx.doi.org/ 10.1179/1743132813Y.0000000232]. [PMID: 23816638]. - PubMed

MeSH terms

Substances

LinkOut - more resources